

April 20, 2023

PROPOSED AMENDMENTS TO ENGROSSED HOUSE BILL NO. 1413

That the Senate recede from its amendments as printed on pages 1429-1430 of the House Journal and page 1181 of the Senate Journal and that Engrossed House Bill No. 1413 be amended as follows:

"SECTION 1. LEGISLATIVE MANAGEMENT STUDY - PRESCRIPTION DRUG COUPON AND FINANCIAL ASSISTANCE PROGRAM UTILIZATION. During the 2023-2024 interim, the legislative management shall consider studying the prevalence and usage of third party payments to reduce or eliminate North Dakota patients' cost sharing and out of pocket costs for prescription drugs, including programs offered by the manufacturer of a prescription drug. The study shall include: the prevalence and usage of third party payments by the manufacturer of prescription drugs and in the North Dakota commercial insurance market. The study shall also include the prevalence and usage of third party payments in government programs and the availability of those programs to uninsured residents, eligibility criteria, and the impact of these program on health care costs and prescription drug pricing.

In conducting the study, input shall be received from the following groups: health insurance carriers, patients or patient groups, prescription drug manufacturers, pharmacy benefit managers, pharmacies or pharmacy association representatives, government and independent academic sources, and any other stakeholder with relevant information. Participants shall disclose any ties or financial compensation received by any entities in the prescription drug supply chain.

The legislative management shall report its findings and recommendations, together with any proposed legislation required to implement the recommendations, to the sixty-ninth legislative assembly."

Renumber accordingly